Mutational enrichments in CTCF binding sites were the strongest in liver hepatocellular carcinoma (RM2 FDR = 1.22 × 10− 12, fold-change (FC) = 1.08), oesophageal adenocarcinoma (FDR = 6.0 × 10− 20, FC = 1.17) and stomach adenocarcinoma (FDR = 6.2 × 10− 11, FC = 1.16), and the pan-cancer cohort. The gene discussed is CTCF; the disease is cancer.